|
Editorial:
Product lifecycle management becomes do or die for pharma
According to a new report from Capgemini, pharmaceutical companies are missing “vital opportunities” to maximize lifetime product values.
The fourth annual Vision & Reality report reveals that more than 90% of senior pharma executives believe that product lifecycle management is important for their future prosperity. Sixty percent of those surveyed also said the importance of product lifecycle management will increase significantly in their organizations over the next five years.
Capgemini says the increased focus on PLM stems from concern over the failure of R&D to provide a steady stream of new blockbuster drugs, leaving ...
Click for full story
Click here for Printable Version 
--Lisa Roner, Editor, eyeforpharma Briefing
Feature:
Marketing ROI: the opportunities and challenges
Today’s pharmaceutical marketplace is a dynamic one filled with increasing competition, shrinking margins and mounting pricing pressures. Finding ways to do more with less has become the order of the day, and pharmaceutical marketers are not immune to the pressure.
Marketing campaigns are challenged to be highly targeted and more customer-centric, but also more effective and cost efficient. Marketing ROI has taken center stage as companies try to combat the effects of looming patent expirations, weakening product pipelines, increasing generic competition and ... Click for full story
Click here for Printable Version
Feature:
Generics manufacturers tout the value of CRM systems
At eyeforpharma’s recent Generic Sales Effectiveness 2004 conference in Amsterdam, many of the event’s speakers cited the benefits of customer relationship management strategies and systems. Unlike many of their counterparts from other industries who have deemed the systems budgetary black holes, several conference participants reported positive returns on both their monetary and time investments.
Stefan Langthaler, Head of Business Systems at ratiopharm said his company is definitely not among the 65% of companies who are unhappy with their CRM implementations. And although he says the road has not always been without bumps, the results have made the journey worthwhile.
The pharmaceut... Click for full story
Click here for Printable Version 
Feature:
Guest Opinion: Good News! Regulation Just Got Tougher
Regulation aims to keep the public safe and the playing field level. We used to marginalise it, as an irksome extra task, its only function to satisfy the regulators.
That was bad business, because compliance – being seen to do the right thing – doesn’t come cheap. And when you invest in any activity, you have to see added value. Today, most companies are integrating PV (pharmocovigilance) into the mainstream operation. It brings performance benefits, and comp... Click for full story
Click here for Printable Version
Feature:
Industry thought leaders critical to marketing success
According to a recent report from Cutting Edge Information (www.CuttingEdgeInfo.com), pharmaceutical companies have increased investments in medical liaison programs over the last decade to create a crucial link with industry thought leaders. Medical science liaisons (MSLs), while able to effectively communicate with key influencing physicians, also play a crucial role in communicating with brand teams.
Pharmaceutical Thought Leaders: Brand Strategies and Product Positioning reveals that pharmaceutical companies are relying on MSLs to ensure thought leader relationships are hitting milestones and executing critical tasks. According to Elio Evangelista, lead analyst on the study for Cutting ... Click for full story
Click here for Printable Version
NEW from eyeforpharma:
eyeforpharma this week launches a new newsletter; focusing on Healthcare Outcomes for the UK pharmaceutical industry. It's relevant to any sales & marketing manager who has responsiblity for the UK market. If you're interested in hearing more, please make sure you fill in your details here.
This Week's News
Contact us:
Editorial and features: lisaroner@eyeforpharma.com
Anything else to do with eyeforpharma or the eyeforpharma Briefing:
psimms@eyeforpharma.com
To unsubscribe, email:
psimms@eyeforpharma.com
Disclaimer:
First Conferences and its agents used their best efforts in collecting and preparing the information published herein. However, First Conferences does not assume, and hereby disclaims, any and all liability for any loss or damage caused by errors, whether such errors resulted from negligence, accident, or other causes.
© 2004 First Conferences Ltd. All rights reserved.
Please click here for legal & privacy notice and terms of use.
|